Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

BACKGROUND: Primary aldosteronism (PA), an overt form of renin-independent aldosterone production, leads to a disproportionately high rate of major adverse cardiovascular events (MACEs). Mounting ...

Researchers at the Federal University of São Carlos (UFSCar) in the state of São Paulo, Brazil, are developing a panel of ...

US researchers say their next step is to extend the test to a wider range of patients, including those with early Alzheimer's who do not have any cognitive symptoms.

FDA approves first blood test for Alzheimer's detection. Simple blood draw replaces expensive scans and spinal taps.

The lumipulse blood test brings renewed hope for earlier diagnosis and treatment for millions of people facing the uncertainty of Alzheimer's disease and other dementias.

The FDA greenlit marketing for the first blood test to help diagnose Alzheimer’s disease. Experts believe this will increase access to Alzheimer’s detection and reduce reliance on expensive ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

The US Food and Drug Administration (FDA) has granted marketing clearance for a new blood test designed to assist in the diagnosis of Alzheimer’s disease, marking it as the first test approved ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that it can help reduce the need for invasive samples or expensive PET scans.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.